| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 1364756 | Bioorganic & Medicinal Chemistry Letters | 2008 | 5 Pages |
Abstract
Starting from a weak omeprazole screening hit, replacement of the pyridine with a 1,3-benzodioxole moiety, modification of the thioether linkage, and substitution of the benzimidazole pharmacophore led to the discovery of nanomolar BRS-3 agonists.
Graphical abstractStarting from a weak omeprazole screening hit, replacement of the pyridine with a 1,3-benzodioxole moiety, modification of the thioether linkage, and substitution of the benzimidazole pharmacophore led to the discovery of nanomolar BRS-3 agonists.Figure optionsDownload full-size imageDownload as PowerPoint slide
Keywords
Related Topics
Physical Sciences and Engineering
Chemistry
Organic Chemistry
Authors
David L. Carlton, Lissa J. Collin-Smith, Alejandro J. Daniels, David N. Deaton, Aaron S. Goetz, Christopher P. Laudeman, Thomas R. Littleton, David L. Musso, Ronda J. Ott Morgan, Jerzy R. Szewczyk, Cunyu Zhang,